Trisomy 21
Chromosome 21; associated with Down syndrome.
Maternal blood screening from 10 weeks of pregnancy for selected chromosome conditions, with core and additional screening options.
Understanding the test
NIPT uses cell-free DNA in maternal blood to estimate the chance of selected chromosome conditions. Core screening covers trisomies 21, 18 and 13. Sex chromosome screening, 22q11.2 deletion screening and optional fetal sex reporting can be discussed during consultation. The selected screening scope and pregnancy circumstances guide interpretation. NIPT is a screening test; a high-risk result requires diagnostic confirmation.
Next-generation sequencing of cell-free DNA from maternal blood, with chromosome-level analysis and fetal-fraction reporting.
What is included
NIPT assesses selected chromosome findings rather than a fixed list of individual genes. The core targets and additional options are listed below.
Chromosome 21; associated with Down syndrome.
Chromosome 18; associated with Edwards syndrome.
Chromosome 13; associated with Patau syndrome.
An X-chromosome copy-number finding; discuss sex chromosome screening separately.
Additional sex chromosome screening. Ask which specific findings are included in the selected test.
A selected chromosome 22 microdeletion target; discuss the value and limitations of expanded screening.
Discuss available additional targets, their limitations and the exact screening scope during consultation.
Optional reporting where requested and appropriate to the pregnancy.
In clinical context
Choosing a test means considering both the genes or regions examined and the types of changes it can detect.
Prenatal screening guidanceYour next step
We’ll discuss the clinical question and confirm testing arrangements, sample requirements, costs and reporting times.